Editas Medicine’s new leadership team on Wednesday reiterated a promise to deliver clinical updates on two CRISPR-based treatments before the end of the year — data the troubled biotech hopes will ease investor doubts about its gene-editing technology.
Other CRISPR companies command multibillion-dollar valuations, but Editas, one of the originals, trades below its IPO price after years of management upheaval and clinical delay.
Create a display name to comment
This name will appear with your comment
